MEDICILON

contact us jpkrencn

お知らせ

企業動向

あなたはここにいる:ホーム > お知らせ > 企業動向

  • 08
    24

    2020

    Medicilon MetID Services

    Metabolite identification (MetID) plays an important role in the research and development of new drugs. During the lead optimization, the identification of metabolites can help to locate the soft spots, so that the chemists can modify the structure of the target compounds and improve their pharmacokinetic properties. 

  • 08
    20

    2020

    A seminar on preclinical R&D strategic cooperation was held between Medicilon

    Yichang, Hubei, Aug 13, 2020 – A seminar on preclinical R&D strategic cooperation was held between Medicilon. INC and Yichang Humanwell Pharmaceutical CO.LTD.

  • 07
    29

    2020

    Development and analysis of inhalation drugs

    The development of orally inhaled and nasal drug products (OINDP) involves a rigorous approach to formulation development, testing, stability and CMC support which are necessary to determine product efficacy, quality, safety and performance.

  • 07
    28

    2020

    Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug

    On July 20, 2020, DAC Biotech’s new ADC drug development, TROP2-ADC---DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process.

  • 07
    20

    2020

    杭州DAC Biotech社のADC薬DAC‐002臨床試験承認におけるMedicilonの支援

    2020年7月20日、DAC Biotech社により開発中のADC医薬品候補TROP2-ADC—DAC-002が、NMPAによる臨床試験実施の承認を受けた。適応症は固形悪性腫瘍である。 Medicilonは、TROP2-ADC—DAC-002開発の前臨床薬物動態試験及び毒性試験を実施し、開発プロセスを加速した。